Aim. Alpha-lipoic acid (ALA) is a potent naturally occurring antioxidant and in the past years several studies suggested the fact that ALA can have positive effects on glucose metabolism. We intended to evaluate in an open-label, non-randomized study, in usual ambulatory settings, the effect intravenous ALA infusion on fructosamine level, in patients with type 2 diabetes and painful peripheral diabetic neuropathy. Patients and methods. 28 consecutive patients with type 2 diabetes and painful peripheral diabetic neuropathy, treated with 10 daily infusions of 600 mg ALA in 300 ml of normal saline, were included in the study. Fructosamine was measured with a colorimetric method. For the analysis of the results we have used the non-parametric Wilcoxon Signed Ranks test. Results. There were 15 women and the mean (± SD) age and duration of diabetes were 59.39 (± 7.92) and 9.46 ± 6.19 yr respectively. Mean (±SD) HbA1c at enrolment was 7.77 ± 1.18 %. The mean (±SD) value of fructosamine decreased significantly from 568.14 (±190.67) µmol/L to 467.10 (±126.98) µmol/L (p < 0.0001). The mean decrease between the first and second measurement was 17.8%, 101.03 (±132.17) µmol/L in absolute term. Conclusions. Decrease in fructosamine concentration can be described at least as a “positive side effect” of ALA used for the treatment of the painful peripheral diabetic neuropathy. As far as we know there is only one study that used fructosamine as a criterion for evaluating the safety and tolerability of orally administred ALA in patients with type 2 diabetes.
Read full abstract